Home > ASME Articles > What Factors Help Shape Long-Term Abstinence from Opioids?
In order to puzzle out those factors, this study examined data from the NIDA Clinical Trials Network study, “Long-Term Follow-Up of START Patients,” a 5-year follow-up of 699 adults with OUD who had been randomized to either methadone or buprenorphine/naloxone in the original START (“Starting Treatment with Agonist Replacement Therapies”) trial.
In their follow-up interviews, 232 (33.2%) participants reported that they had achieved 5-year abstinence from heroin. Of that 232, 145 (20.7% of the total) had remained abstinent from both heroin and other opioids.
Compared to non-abstinent individuals, those in both categories of opioid abstinence (heroin only or both heroin and other opioids) had fewer health and social function problems at the final follow-up.
Analysis also found that cocaine users and injection drug users were less likely to achieve 5-year heroin abstinence, and Hispanics (vs. whites) and those treated in clinics on the West Coast (vs. East) were less likely to achieve 5-year abstinence from both heroin and other opioids.
For both abstinence groups, abstinence was positively associated with older age at first opioid use, lower impulsivity, longer duration of treatment for OUD, and greater social support.
Conclusions: Reducing cocaine use and injection drug use and increasing social support and retention in treatment may help maintain long-term abstinence from opioids among individuals treated with buprenorphine/naloxone or methadone.
Find it in the CTN Library